Elza C de Bruin (Elza DeBruin)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 14

Top Topics

Epidermal Growth Factor Receptor

Patient Reported

Metastatic Breast Cancer

Top Venues

Nature communications

NPJ breast cancer

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Constance A Sobsey, Bjoern C Froehlich, Georgia Mitsa, Sahar Ibrahim, Robert Popp, René Peiman Zahedi, Elza C de Bruin, Christoph H Borchers, Gerald Batist
mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors. Cancer research communications 4 (8) (2024)
Sebastijan Hobor, Maise Al Bakir, Crispin T Hiley, Marcin Skrzypski, Alexander M Frankell, Bjorn Bakker, Thomas B K Watkins, Aleksandra Markovets, Jonathan R Dry, Andrew P Brown, Jasper van der Aart, Hilda van den Bos, Diana Carolina Johanna Spierings, Dahmane Oukrif, Marco Novelli, Turja Chakrabarti, Adam H Rabinowitz, Laila Ait Hassou, Saskia Litière, D Lucas Kerr, Lisa Tan, Gavin P Kelly, David Allan Moore, Matthew J Renshaw, Subramanian Venkatesan, William Hill, Ariana Huebner, Carlos Martínez-Ruiz, James R M Black, Wei Wu, Mihaela Angelova, Nicholas McGranahan, Julian Downward, Juliann Chmielecki, Carl Barrett, Kevin Litchfield, Su Kit Chew, Collin M Blakely, Elza C de Bruin, Floris Foijer, Karen H Vousden, Trever G Bivona, null null, Robert Edward Hynds, Nnennaya Kanu, Simone Zaccaria, Eva Grönroos, Charles Swanton
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. Nature communications 15 (1) (2024)
Sebastijan Hobor, Maise Al Bakir, Crispin T Hiley, Marcin Skrzypski, Alexander M Frankell, Bjorn Bakker, Thomas B K Watkins, Aleksandra Markovets, Jonathan R Dry, Andrew P Brown, Jasper van der Aart, Hilda van den Bos, Diana Carolina Johanna Spierings, Dahmane Oukrif, Marco Novelli, Turja Chakrabarti, Adam H Rabinowitz, Laila Ait Hassou, Saskia Litière, D Lucas Kerr, Lisa Tan, Gavin P Kelly, David Allan Moore, Matthew J Renshaw, Subramanian Venkatesan, William Hill, Ariana Huebner, Carlos Martínez-Ruiz, James R M Black, Wei Wu, Mihaela Angelova, Nicholas McGranahan, Julian Downward, Juliann Chmielecki, Carl Barrett, Kevin Litchfield, Su Kit Chew, Collin M Blakely, Elza C de Bruin, Floris Foijer, Karen H Vousden, Trever G Bivona, null null, Robert Edward Hynds, Nnennaya Kanu, Simone Zaccaria, Eva Grönroos, Charles Swanton
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. Nature communications 15 (1) (2024)
Constance A Sobsey, Bjoern C Froehlich, Georgia Mitsa, Sahar Ibrahim, Robert Popp, René Peiman Zahedi, Elza C de Bruin, Christoph H Borchers, Gerald Batist
mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors. Cancer research communications 4 (8) (2024)
Constance A Sobsey, Bjoern C Froehlich, Georgia Mitsa, Sahar Ibrahim, Robert Popp, René Peiman Zahedi, Elza C de Bruin, Christoph H Borchers, Gerald Batist
mTORC1-driven protein translation correlates with clinical benefit of capivasertib within a genetically preselected cohort of PIK3CA-altered tumours. Cancer research communications (2024)
Sebastijan Hobor, Maise Al Bakir, Crispin T Hiley, Marcin Skrzypski, Alexander M Frankell, Bjorn Bakker, Thomas B K Watkins, Aleksandra Markovets, Jonathan R Dry, Andrew P Brown, Jasper van der Aart, Hilda van den Bos, Diana Carolina Johanna Spierings, Dahmane Oukrif, Marco Novelli, Turja Chakrabarti, Adam H Rabinowitz, Laila Ait Hassou, Saskia Litière, D Lucas Kerr, Lisa Tan, Gavin P Kelly, David Allan Moore, Matthew J Renshaw, Subramanian Venkatesan, William Hill, Ariana Huebner, Carlos Martínez-Ruiz, James R M Black, Wei Wu, Mihaela Angelova, Nicholas McGranahan, Julian Downward, Juliann Chmielecki, Carl Barrett, Kevin Litchfield, Su Kit Chew, Collin M Blakely, Elza C de Bruin, Floris Foijer, Karen H Vousden, Trever G Bivona, null null, Robert Edward Hynds, Nnennaya Kanu, Simone Zaccaria, Eva Grönroos, Charles Swanton
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. Nature communications 15 (1) (2024)
Constance A Sobsey, Bjoern C Froehlich, Georgia Mitsa, Sahar Ibrahim, Robert Popp, René Peiman Zahedi, Elza C de Bruin, Christoph H Borchers, Gerald Batist
mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors. Cancer research communications 4 (8) (2024)
Sebastijan Hobor, Maise Al Bakir, Crispin T Hiley, Marcin Skrzypski, Alexander M Frankell, Bjorn Bakker, Thomas B K Watkins, Aleksandra Markovets, Jonathan R Dry, Andrew P Brown, Jasper van der Aart, Hilda van den Bos, Diana Carolina Johanna Spierings, Dahmane Oukrif, Marco Novelli, Turja Chakrabarti, Adam H Rabinowitz, Laila Ait Hassou, Saskia Litière, D Lucas Kerr, Lisa Tan, Gavin P Kelly, David Allan Moore, Matthew J Renshaw, Subramanian Venkatesan, William Hill, Ariana Huebner, Carlos Martínez-Ruiz, James R M Black, Wei Wu, Mihaela Angelova, Nicholas McGranahan, Julian Downward, Juliann Chmielecki, Carl Barrett, Kevin Litchfield, Su Kit Chew, Collin M Blakely, Elza C de Bruin, Floris Foijer, Karen H Vousden, Trever G Bivona, null null, Robert Edward Hynds, Nnennaya Kanu, Simone Zaccaria, Eva Grönroos, Charles Swanton
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. Nature communications 15 (1) (2024)
Sebastijan Hobor, Maise Al Bakir, Crispin T Hiley, Marcin Skrzypski, Alexander M Frankell, Bjorn Bakker, Thomas B K Watkins, Aleksandra Markovets, Jonathan R Dry, Andrew P Brown, Jasper van der Aart, Hilda van den Bos, Diana Carolina Johanna Spierings, Dahmane Oukrif, Marco Novelli, Turja Chakrabarti, Adam H Rabinowitz, Laila Ait Hassou, Saskia Litière, D Lucas Kerr, Lisa Tan, Gavin P Kelly, David Allan Moore, Matthew J Renshaw, Subramanian Venkatesan, William Hill, Ariana Huebner, Carlos Martínez-Ruiz, James R M Black, Wei Wu, Mihaela Angelova, Nicholas McGranahan, Julian Downward, Juliann Chmielecki, Carl Barrett, Kevin Litchfield, Su Kit Chew, Collin M Blakely, Elza C de Bruin, Floris Foijer, Karen H Vousden, Trever G Bivona, null null, Robert Edward Hynds, Nnennaya Kanu, Simone Zaccaria, Eva Grönroos, Charles Swanton
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. Nature communications 15 (1) (2024)
Lorna Hopcroft, Eleanor M Wigmore, Stuart Charles Williamson, Susana Ros, Cath Eberlein, Jennifer I Moss, Jelena Urosevic, Larissa S Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J A Goodwin, Brandon S Willis, Claire Rooney, Elza C de Bruin, Simon T Barry
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models. NPJ breast cancer 9 (1) (2023)
Lorna Hopcroft, Eleanor M Wigmore, Stuart Charles Williamson, Susana Ros, Cath Eberlein, Jennifer I Moss, Jelena Urosevic, Larissa S Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J A Goodwin, Brandon S Willis, Claire Rooney, Elza C de Bruin, Simon T Barry
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models. NPJ breast cancer 9 (1) (2023)
Lorna Hopcroft, Eleanor M Wigmore, Stuart Charles Williamson, Susana Ros, Cath Eberlein, Jennifer I Moss, Jelena Urosevic, Larissa S Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffman, Daniel Sutton, Stewart Jones, Richard J A Goodwin, Brandon S Willis, Claire Rooney, Elza C de Bruin, Simon T Barry
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models. NPJ breast cancer 9 (1) (2023)
Lillian M Smyth, Gerald Batist, Funda Meric-Bernstam, Peter Kabos, Iben Spanggaard, Ana Lluch, Komal Jhaveri, Andrea Varga, Andrea Wong, Alison M Schram, Helen Ambrose, T Hedley Carr, Elza C de Bruin, Carolina Salinas-Souza, Andrew Foxley, Joana Hauser, Justin P O Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Myria Nikolaou, Gaia Schiavon, Pedram Razavi, Udai Banerji, José Baselga, David M Hyman, Sarat Chandarlapaty
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. NPJ breast cancer 7 (1) (2021)
Tereza Vaclova, Ursula Grazini, Lewis S C Ward, Daniel O'Neill, Aleksandra Markovets, Xiangning Huang, Juliann Chmielecki, Ryan Hartmaier, Kenneth S Thress, Paul D Smith, J Carl Barrett, Julian Downward, Elza C de Bruin
Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers. Nature communications 12 (1) (2021)